Lenvatinib and Depth of Response in Advanced uHCC: Insights From REFLECT

Opinion
Video

An expert discusses how recent analyses from the REFLECT trial in unresectable hepatocellular carcinoma (uHCC) demonstrate that both achieving objective response and greater depth of response correlate with improved survival outcomes. The depth of response serves as a potentially valuable early biomarker for prognosis and treatment decisions, with deeper responses associated with better overall survival among responders.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • What role do the overall response and depth of response play in guiding treatment decisions for advanced uHCC?
      • Review recent evidence from REFLECT looking at characterization of tumor response.
      • Please discuss the clinical implications from the best overall response, depth of response, and overall survival among responders’ data.
      • What are your thoughts on looking at the depth of response as a marker for clinical outcomes?

      Newsletter

      Stay up to date on practice-changing data in community practice.

      Subscribe Now!
      Recent Videos
      Case 3 (cont.): Management of Treatment-Associated ILD/Pneumonitis
      Case 3 (cont.): Management of Treatment-Associated ILD/Pneumonitis
      Management of ADC-Related AEs
      Management of ADC-Related AEs
      1 expert is featured in this series.
      Current Practices and Initial Treatment Considerations for Patients With cGVHD
      DLBCL Subtype Response Patterns: Optimizing Treatment Selection
      DLBCL Subtype Response Patterns: Optimizing Treatment Selection
      Evolving Treatment Strategies in DLBCL: Real-World Clinical Experience
      Evolving Treatment Strategies in DLBCL: Real-World Clinical Experience
      2 experts in this video
      The Evolving Role of Lenvatinib in the HCC Therapeutic Landscape
      2 experts in this video
      Second-Line Therapy in Advanced HCC: Treatment Considerations and Evolving Options
      HER2-Mutated NSCLC: Second-Line Treatment Selection and Emerging Approaches
      HER2-Mutated NSCLC: Second-Line Treatment Selection and Emerging Approaches
      HER2 Mutations in NSCLC
      HER2 Mutations in NSCLC
      1 expert in this video
      Treatment Implementation and Long-Term Considerations in BPDCN
      Related Content
      First Patient Dosed With IO-108 in Phase 1b/2 HCC Trial

      First Patient Dosed With IO-108 in Phase 1b/2 HCC Trial

      Jordyn Sava
      March 3rd 2025
      Article

      A global, randomized, phase 1b/2 trial is evaluating IO-108 in patients with metastatic and/or unresectable hepatocellular carcinoma.

      Read More

      Tailoring Treatments to Better Outcomes in Liver Cancer

      Tailoring Treatments to Better Outcomes in Liver Cancer

      Jordyn Sava;Susanne G. Warner, MD
      October 13th 2023
      Podcast

      In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

      Listen

      Nivolumab Plus Ipilimumab Improves OS and Response in Frontline uHCC

      Nivolumab Plus Ipilimumab Improves OS and Response in Frontline uHCC

      Jordyn Sava
      January 24th 2025
      Article

      The CheckMate 9DW study demonstrated the efficacy and manageable safety of first-line nivolumab plus ipilimumab in patients with unresectable hepatocellular carcinoma.

      Read More

      TACE Plus Camrelizumab and Rivoceranib Boosts PFS in Unresectable HCC

      TACE Plus Camrelizumab and Rivoceranib Boosts PFS in Unresectable HCC

      Russ Conroy
      January 24th 2025
      Article

      TACE with camrelizumab and rivoceranib significantly improves PFS in unresectable HCC, per phase 2 CARES-005 study results.

      Read More

      Amezalpat Gains FDA Orphan Drug Status in HCC

      Amezalpat Gains FDA Orphan Drug Status in HCC

      Jordyn Sava
      January 8th 2025
      Article

      The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy and safety with atezolizumab and bevacizumab in frontline treatment.

      Read More

      Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC

      Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC

      Targeted Oncology Staff
      December 21st 2024
      Article

      During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.

      Read More